We identified by a monoclonal antibodybased immunoradiometric assay high concentrations of 
several AD brains revealed levels varying from 12 to 295 ng/g of tissue (mean, 116 ng/g) compared with 1-11 ng/g of tissue (mean, 5 ng/g) found in comparable areas of control brains. Immunocytochemistry performed with the anti-PTP monoclonal antibodies demonstrate PTP immunoreactivity within large pyramidal neurons-many of which contain neurofibrillary tangles in both AD and Down syndrome. Less accumulation was observed in astrocytes, and some PTP immunoreactivity was found extracellularly. The highest number of labeled cells in AD and Down syndrome was seen in the hippocampal formation. Fewer positive-staining cells were noted in normal and disease control brains. We conclude, therefore, that an exocrine pancreatic protein is present in the central nervous system of normal individuals at low levels; in AD brain concentrations of this protein are much higher.
We have been studying an unusual pancreatic exocrine protein designated as the pancreatic thread protein (PTP) (1) . This protein is found in great abundance in the acinar cells and reaches concentrations of 1-4 mg/ml in normal pancreatic fluid as measured by a monoclonal antibody (mAb)-based immunoradiometric assay (M-IRMA). PTP in its monomeric form has an apparent Mr of :414,000, consists of a single polypeptide chain, and is rich in aromatic amino acids. The solubility characteristics of the protein are unusual, such that it undergoes a pH-dependent, reversible, fibril formation between pH values of 5.4 and 9.2. The protein forms long single-stranded, smooth thread-like structures of 7-to 10-nm width when pancreatic fluid is allowed to stand for several days at 4°C as viewed by the electron microscope (1) . Thus, PTP represents one of the major secretory products of the exocrine pancreas in man. Another pancreatic protein has been described, called pancreatic stone protein (2) ; recent protein sequence data demonstrate that pancreatic stone protein is identical to PTP (3) . An homologous protein with paired helical structure'has been identified in bovine pancreas (4) .
Because of the insolubility of the protein at physiologic pH and the physical appearance of the fibrils by electron microscopy, PTP reminded us of some fibrils seen in neuritic plaques and neurofibrillary tangles (NFT) of Alzheimer disease (AD). Although an exocrine pancreatic protein has heretofore not been described in the central nervous system, we examined the brain for the presence of PTP immunoreactivity with a combination of mAbs each directed against a different epitope on the isolated purified native pancreatic form of the protein. To our surprise we found high levels of PTP immunoreactivity in AD brain.
MATERIALS AND METHODS
Tissue and Histopathologic Diagnosis. Brain tissue from patients with AD enrolled in the Massachusetts General Hospital AD Research Center, Down syndrome (DS), normal controls, and other central nervous system diseases was obtained at postmortem examination and harvested within 12 hr of death for snap freezing at -800C in isopentane and fixation. Paraffin tissue sections (8-10 pkm) were dewaxed and stained with Luxol fast blue/hematoxylin/eosin, Bodian silver impregnation, Bielschowski's silver impregnation, and Congo red. The diagnosis ofAD was rendered using threshold criteria reported by Khachaturian (5) .
Immunohistochemical Studies. Adjacent cryostat and dewaxed, rehydrated paraffin sections 12 ,um thick were equilibrated in phosphate-buffered saline (PBS). The sections were incubated with mAb 9 to PTP or mAb to neurofilament antigen (mixture of mAbs against all three Mr forms; Sternberger and Meyer Co., Baltimore) for 1 hr and 16 hr, respectively. Immunoreactive cells were detected using the avidinbiotin-horseradish peroxidase complex method (ABC; Vector Laboratories) with 3,3'-diaminobenzidine as the chromogen. The sections were examined by light microscopy, and the number of immunolabeled cells in 20 adjacent (x250) fields was determined.
Preparation of Brain Extracts. Frozen samples of brain tissue were weighed and homogenized with a Polytron homogenizer in 5 vol of PBS containing 0.1% NaN3. Extracts were centrifuged at 10,000 x g for 15 min at 40C. The supernatant was used for the measurement of PTP immunoreactivity and protein content (6) . The pellet was resuspended in PBS and used for the determination of DNA content as described (7).
Immunochemical Mapping. Purified human PTP (1) was diluted from 1 to 100 ng/ml in 20% calf serum or 10% bovine serum albumin-PBS to prepare standards. Epitope-mapping studies were done by comparing the binding profiles of the PTP standard to that found in AD brain. containing -100,000 cpm in 20% calf serum in PBS). After a 4-hr incubation at 20'C, beads were washed, and bound radioactivity was determined by a y well counter. M-IRMA. Three mAbs directed against different epitopes on human PTP (1) were used to construct a sensitive three-site immunoradiometric assay (iRMA). Details regarding the construction of such assays have been reported (8, 9) . mAbs 7 and 10 were used as capture antibodies on the solid-phase support, and I251-labeled mAb 9 was used as the tracer. We measured immunoreactivity in 200 tzl of tissue extract or PTP standard by a "forward sandwich" overnight assay at 20'C (8, 9) . PTP concentrations were determined from the standard curve (linear from 1 to 10 ng/ml). The lower limit of sensitivity was found to be 50 pg of PTP per ml when diluted in serum. Results were expressed as ng/g (wet weight), ng/mg of protein, or ng/mg of DNA.
Gel Electrophoresis. Purified PITP, normal pancreatic fluid, and saline extracts prepared from AD brain were analyzed on 15% polyacrylamide gels in the presence of sodium dodecyl sulfate (SDS). After electrophoresis, the wet gels were cut into 2-mm fractions with a gel slicer. Proteins were eluted from the gel fractions by shaking 24-72 hr at 4°C with 1 ml of PBS containing 1% bovine serum albumin and 0.2% NaN3. The eluates were analyzed for PTP-binding activity by M-IRMA. Prestained protein molecular weight markers (BioRad) were used to estimate the molecular weight of the material with PTP immunoreactivity. fected by the method of data expression with the notable exception of cerebellum, where PTP levels were lower than other areas when expressed as ng/mg of DNA.
RESULTS
Epitope Mapping of PTP in AD Brain. To determine whether all three distinct and separate epitopes found on the pancreatic form ofPTP were present in AD brain, we used the mAbs in combination in the construction of nine different IRMAs (Fig. 2) . The binding profiles of PTP in pancreatic fluid and PTP immunoreactivity in AD brain are similar. It is noteworthy that these three epitopes are probably not repeating because the homologous IRMAs of 7/7*, 9/9*, and 10/10* (indicating that the capture and detecting antibody are the same) gave no or very low binding activity. We conclude from these observations that the epitopes detected by the mAbs in the native pancreatic PTP and species found in AD brain are the same.
Quantitative Analysis of Soluble PTP Immunoreactivity in Brain Tissue. To assess the possible significance of the above findings we expanded our investigations and analyzed soluble extracts from 71 brain tissue samples derived from six subjects with AD, four normal controls, and three other central nervous system diseases (schizophrenia, multi-infarct dementia, and Parkinson disease). Brain areas 4, 7b, 8/9, 11, 17, 20/21, 40, 45, and cerebellum were analyzed from the same subject in most cases. Fig. 3 illustrates representative PTP values from similar areas of the brain for the three patient groups.
Normal controls have low but detectable levels of PTP immunoreactivity in various regions of the brain. Concentrations ranged from 1 to 11 ng/g of tissue (wet weight) with a mean value for normal brain of 5 ng/g of tissue. In contrast five of six patients studied with AD were found to have PTP levels above the normal range. Levels varied from 12 to 295 ng/g with a mean of 116 ng/g. In general, there appeared to be little variations of PTP concentrations between several areas of brain derived from the same patient (see Fig. 1 ). It is noteworthy that the other and only case of AD where PTP levels were found to be within the normal range in areas 4, 8/9, 11, 17, 20/21, 45, and cerebellum revealed no pathologic changes in these regions characteristic of the disease. In this individual neuritic plaques and NFT were found only in the hippocampal formation and amygdala; PTP immunoreactivity, however, was demonstrated in the involved neurons in this case by histochemical staining (data not shown). Finally, PTP immunoreactivity measured in nine different areas varied from 4 to 18 ng/g in schizophrenia, Parkinson Molecular Forms of Soluble PTP in AD Brains. We determined the molecular weight of the material with binding activity and compared these results in AD brain to pancreatic fluid PTP as shown in Fig. 4 . It was of interest that all four AD brains studied had the same species of PTP that migrated slightly slower than the major peak of the purified pancreatic PTP (Mr, 414,000). The range of AD brain PTP immunoreactivity varied between 17,000 and 20,000. Thus, the soluble PTP found in AD brain has a definable molecular form (s) by SDS/PAGE similar to, but slightly higher than, that found in pancreatic fluid.
Immunohistochemical Staining and Cellular Location. With antineurofilament antibody, abundant NFT were present in brains from five patients with AD and four others with DS as shown in Fig. 5 . Although there was variability in the density of NFT among the cases, in AD the highest densities were present in the frontal cortex, including areas 24, 11, and 4, the temporal association cortex (area 20/21) and the hippocampal formation. Lower but moderate densities of NFT were seen in the parietal cortex (area 40) and primary visual cortex (area 17). NFT were either rare or absent in the cerebellum. In DS, NFT and the hippocampus, an already recognized histopathological distinction between AD and DS. In addition, NFT occurred infrequently in both area 17 and the cerebellum. Control brains had only rare scattered NFT.
Cells immunolabeled with mAb 9 were seen in normal brains and brains from patients with AD and DS. However, the density of immunolabeled cells and the intensity of immunolabeling were considerably less in control brains compared with either AD or DS (Fig. 5) . In AD, the highest densities of PTP-containing cells were located in area 24 and the hippocampal formation. All other regions manifested similar densities of PTP-containing cells except for the cerebellum, which was devoid of them. Large pyramidal neurons were most conspicuously labeled, and surprisingly those cells also appeared to either contain NFT or represent the population of neurons that characteristically develop NFT in AD, as illustrated in Fig. 6 . In addition, rare neuritic plaques were visualized with mAb 9. To quite a varied extent, reactive fibrous astrocytes were immunoreactive for PTP, but in contrast to neurons in which the immunolabeling was smooth and fibrillary, the immunoreactivity in astrocytes appeared beaded and granular (data not shown). Finally, the neuropil throughout all regions of cerebral cortex contained extremely fine, thread-like fibrils immunoreactive for PTP (data not shown). There did not appear to be an association between PTP immunoreactivity and blood vessels or white matter, and small neurons usually lacked PTP immunoreactivity.
DISCUSSION
This study demonstrates the presence of high levels of PTP immunoreactivity in many areas of the AD brain compared in all four AD brains studied (Fig. 4) but not to the r protein (10) . It will be of interest to determine whether some of our 50 mAbs prepared against PTP "decorates" both Pronase-digested PHF and fibrillar PTP by immunoelectron microscopy. Proteins found in neuritic plaques and NFT of AD have recently been isolated and characterized biochemically, immunohistochemically, structurally, and by the preparation of cDNAs that were subsequently cloned and sequenced; one of the amyloid proteins (,8 protein) initially described by Glenner and Wong (12) has been cloned and sequenced. The A4 amyloid protein found in neuritic plaques and blood vessels has been determined to be a component of a 695-amino acid precursor-a protein postulated to function as a glycosylated cell-surface receptor (13, 14) . The gene coding for A4 is located on chromosome 21 (14) (15) (16) (17) , but apparently this gene is not linked to the familial form of the disease (18) . There appears to be little, if any, protein sequence homology between amyloid A4 and P protein, their higher molecular weight precursor, and PTP (1). Several other proteins have been described, including ubiquitin, ALZ-50, microtubularassociated protein T, microtubular-associated protein 2, and neurofilament protein, none of which appear to be related to PTP at the present time (19) (20) (21) (22) . More recently, a serine protease inhibitor-namely, a1-antichymotrypsin has been found in AD amyloid deposits (23) . Whether PTP has a function as an antiprotease or is involved in some proteinprotein interactions important in cellular transport and/or secretion of other proteins or enzymes remains to be determined. The fact that soluble PTP found in the brain has a higher molecular weight than the pancreatic form may have significance in this regard.
PTP immunoreactivity was found in normal brain at low levels. One of the central questions to be addressed is whether PTP accumulates in normal brain during the aging process. Indeed, it will be of interest to determine whether high levels of PTP immunoreactivity are present in brain before the development of clinical symptoms of AD (24, 25) .
Other central nervous system disease tissues will also need to be extensively studied to determine whether high concentrations of PTP are a specific property or marker of AD. It is noteworthy that some amyloid proteins are also deposited in the brains of animals as a function of age (26) . Because an homologous form of PTP is also present in bovines (4), a search for increasing brain PTP levels in aging animals will be useful.
In the present investigation we examined, to a limited extent, the cellular distribution of PTP within the central nervous system. PTP was localized both within cells and either extracellularly or in fine processes within the neuropil. 
